Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection
about
Respiratory syncytial virus-neutralizing serum antibody titers in infants following palivizumab prophylaxis with an abbreviated dosing regimen.Preventing hospitalizations for respiratory syncytial virus infectionLocal variations in the timing of RSV epidemicsVaccination strategies against respiratory syncytial virus.Product review on the monoclonal antibody palivizumab for prevention of respiratory syncytial virus infection.Occurrence of human respiratory syncytial virus in summer in Japan.Outcomes of Respiratory Syncytial Virus Immunoprophylaxis in Infants Using an Abbreviated Dosing Regimen of PalivizumabManagement of Acute Respiratory Failure in Patients With Hematological Malignancy.Editorial Commentary: Can a Reduced-Dose Prophylaxis Schedule Provide Adequate Coverage Against Respiratory Syncytial Virus Infection?Establishing Correlates of Protection for Vaccine Development: Considerations for the Respiratory Syncytial Virus Vaccine Field.Adherence and outcomes: a systematic review of palivizumab utilization.A natural human monoclonal antibody targeting Staphylococcus Protein A protects against Staphylococcus aureus bacteremia.Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants.Genetic variations in the fusion protein of respiratory syncytial virus isolated from children hospitalized with community-acquired pneumonia in China.Prévenir les hospitalisations pour l’infection par le virus respiratoire syncytial.
P2860
Q33596700-E6519464-7213-48FA-A46A-86EC67881FECQ36082195-A8741C5A-36CB-475D-BE15-1D69D318ADFEQ36190280-7C606F14-73D2-4EAD-9380-08465DBD4812Q37469280-829DB738-538D-4C05-9534-47F83E8DBC0FQ38671952-C92F03A9-7DF3-4313-837D-33254439631CQ39341793-11E4C87A-D8EE-40B5-A1B9-DC46EB7F0443Q40848855-D6507271-05BF-4F4A-9869-0335CF0B3796Q41047392-C40D6ABE-7C86-4A87-840D-752DB8D8A0B8Q45342359-86FE4744-7D81-436D-93E9-FE0E907E716AQ47553316-6C77F063-6A2D-42E7-BD61-D995CF80ACCFQ47582466-1F59CC7B-1913-4D4F-83EC-1B151D9A77D2Q48174220-BA5BFE68-AB2E-4286-A212-BB77FD9B1167Q49720574-E2B9D1D7-CAC3-4E66-AEEA-09C4EC61A98DQ52655304-40C6BEE9-53D7-45DE-9259-6AB31C9F3766Q53932344-BC3AF3AE-390D-4E93-9A9D-6A9D7B0612DD
P2860
Efficacy and optimization of palivizumab injection regimens against respiratory syncytial virus infection
description
2015 nî lūn-bûn
@nan
2015 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
Efficacy and optimization of p ...... tory syncytial virus infection
@ast
Efficacy and optimization of p ...... tory syncytial virus infection
@en
type
label
Efficacy and optimization of p ...... tory syncytial virus infection
@ast
Efficacy and optimization of p ...... tory syncytial virus infection
@en
prefLabel
Efficacy and optimization of p ...... tory syncytial virus infection
@ast
Efficacy and optimization of p ...... tory syncytial virus infection
@en
P2860
P1433
P1476
Efficacy and optimization of p ...... tory syncytial virus infection
@en
P2093
Alexander Gutfraind
P2860
P304
P356
10.1001/JAMAPEDIATRICS.2014.3804
P407
P577
2015-04-01T00:00:00Z